DOCSLIB.ORG

National Cannabis Industry Association's Response to the U.S. Food and Drug Administration's Request for Public Comments On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Cannabis Industry Association's Response to the U.S. Food and Drug Administration's Request for Public Comments On National Cannabis Industry Association’s Response to the U.S. Food and Drug Administration’s Request for Public Comments on Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds May 2019 National Cannabis Industry Association INDUS ABIS TR N Y N AS A S C O L C A I N A T O I I O T N ADVOCACY. EDUCATION. COMMUNITY. A N T h g e r C .o an try nabisIndus May 31, 2019 INDUS ABIS TR N Y N AS A S Food and Drug Administration C O L C A I Division of Dockets Management N A T O I I O Docket FDA-2019-N-1482 T N A HFA-305 N 5630 Fishers Lane T h g Room 1061 e r C .o Rockville, MD 20852 an try nabisIndus Re: Public Comments Submission (Docket FDA-2019-N-1482) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds Dear Sir/Madam: On behalf of the National Cannabis Industry Association (“NCIA”), and in response to the U.S. Food and Drug Administration’s (“FDA”) request for comments on Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds, published in the April 3, 2019 edition of the Federal Register, we hereby submit the attached public comments and relevant prior work. In addition to our specific expertise, and on behalf of our Association members and the cannabis and CBD/hemp industries at large, we have formed a coalition of cannabidiol (“CBD”)/hemp entrepreneurs, scientists, medical professionals, and food and drug lawyers to provide public comment to FDA and to answer specific questions posed by FDA, to provide general context about the industry, and to highlight work that we have previously done on packaging, labeling, and lab testing that could inform FDA rulemaking. This coalition was formed for the sole purpose of providing public comments to FDA. Coalition ​ ​ members have collaborated for weeks to prepare this submission and are listed below. We are grateful that FDA is accepting public comments from the CBD/hemp industry and interested parties. As leading advocates for this nascent industry, NCIA looks forward to providing useful information to help inform FDA in their rulemaking process. Today, NCIA represents nearly 2,000 members, including CBD-related commercial manufacturers, as well as cannabis and ancillary business leaders, legal professionals, specialized researchers and scientists, and public health experts throughout the United States. Because of our diverse membership, NCIA is uniquely positioned to provide recommendations to FDA that address potential benefits and industry standards for regulatory oversight of products containing cannabis or cannabis-derived compounds. Given the substantial interest in this topic and the need for regulations and standardization throughout the industry, NCIA and this coalition are providing specific insight into all facets FDA would like to examine, including health and safety risks, manufacturing and product quality, and marketing, labeling, and sales. Additionally, NCIA and our coalition have expert 2 knowledge and access to relevant information to inform FDA as it considers proper regulations overseeing cannabis-derived compounds to ensure product quality and consistency. As consumption of CBD and the popularity of other hemp-related materials has dramatically increased in recent years, NCIA is the leading organization to inform appropriate regulators about cannabis-derived products under the purview of FDA. We are committed to continuing to work with Federal regulators, Congress, and State and local stakeholders to implement effective regulations supported by in-depth research, analysis, and input from diverse stakeholders and experts. NCIA and our coalition appreciate the opportunity to provide written comments to FDA on such an important topic and we thank you in advance for considering our expert views. We look forward to working with FDA to implement regulations and improve public safety for the cannabis and cannabis-derived products marketplace. If you have any questions regarding our submission or would like further information, please feel to contact NCIA’s Director of Public Policy, Andrew Kline, at (720) 547-6218 or ​ ​ [email protected]. Sincerely, Aaron Smith Andrew Kline Executive Director Director of Public Policy National Cannabis Industry Association National Cannabis Industry Association Khurshid Khoja Henry G. Wykowski, Esq. Principal, Greenbridge Corporate Counsel Wykowski Law Board Vice Chair, National Cannabis Industry General Counsel to the National Cannabis Association Industry Association Alena Rodriguez Jonathan Havens Managing Director Partner | Co-Chair, Cannabis Law | Chair, Rm3 Labs Food & Beverage 3 Saul Ewing Arnstein & Lehr LLP Dr. Paul Muchowski Andrew Livingston CEO and Founder Vice President, Research and Analysis Dr. Paul’s VS Strategies Étienne Fontán Jessica Billingsley Vice President Co-Founder & CEO Berkeley Patients Group MJ Freeway AC Braddock Steve DeAngelo CEO Chairman Emeritus Eden Labs LLC Harborside / FLRish, Inc. Eduardo Provencio Jeremy Riggle, Ph.D. General Counsel Chief Science Officer Mary’s Medicinals Mary’s Medicinals Douglas Fischer Joseph W. Hickey Sr. General Counsel Founding Board Member Greenlane Holdings Kentucky Hemp Industries Association Chris Elawar Vanessa Marquez Co-founder Co-founder CBD Care Garden CBD Care Garden 4 Adam Orens Alex Berger Economist - Founder Attorney Marijuana Policy Group Emerge Law Group James Schwartz BSN, LNC Stuart Bennett CEO Chief Revenue Officer Cascade High Organics Gabriella’s Kitchen, Global Lab Analytics Jessica Wasserman. Esq. Michael Scherr Partner CEO & Founder Greenspoon Marder LLP Aria Brands Richard Y. Cheng, JD, CHC Ian Stewart Partner, Health Care Industry Sector Wilson Elser Moskowitz Edelman & Dicker DLA Piper, LLP LLP Dr. Theodore Search Tyler Williams Medical Advisor VP of Operations GoFire ASI Cannabis Safety and Quality Jason Winkler Ramon Alarcon President CEO Novium Wellness Insight Technologies, Inc 5 Jarett Burke Gregg Steinberg CEO CEO Jade House Midwest GrowCentia Susan Ameel Josh Levine Global Regulatory Risk Advisors, LLC Global Regulatory Risk Advisors, LLC Christina Sasser Randy Miles CEO Total Cannabis Solutions Vital Leaf Michael Cooper Tom Downey Managing Member Attorney MadisonJay Solutions LLC Ireland Stapleton Pryor and Pascoe, PC Daniel Smith Dylan C. Summers Vice President, State and Federal Policy Chief Marketing Officer VS Strategies Lazarus Naturals Steven Hawkins Herrick Fox Executive Director CEO and Co-Founder Marijuana Policy Project Meristem Farms, LLC 6 Robert Gold Steve Goldner Managing Attorney CEO and Founder AEGIS Law Pure Green Colte Koen Arnaud Dumas de Rauly CEO Co-CEO of The Blinc Group Hempsun Farms Products Chairman of the ISO Standards on Vaping Thomas Caristo Joshua Awad TEQ Analytical Labs Co-Founder and COO Honest Paws Corey Pease Mike LeBlanc CEO Chief of Brand Development Holistic Hemp Healing Chae Manufacturing Elisa J. Stewart, Esq. Andrew Schwartz, Ph.D. Chief Compliance Officer Co-Founder Greenbrier Holdings, LLC Mokiobi Tess Melody Taylor Jillian Hishaw TAYLOR + tess Founder/Director, Family Agriculture Resource Management Service (F.A.R.M.S.) 7 Gregory Candelario Alex Buscher CEO & Founder Founding Attorney Tissue Culture Research & Development Buscher Law LLC Mark Caredda Hillary King Bucklin Chief Operating Officer Owner Hemp Hydrate International Holdings Ltd. H. King & Co. Simon Dufour Susan Agostinelli Principal President & CEO Hall & Company Certified Public Accountants Pure Hermosa Shira Adler Crystal A. Banse Founder & CEO Founder & CEO Synergy by Shira Adler Banse Law Group Elisa J. Stewart, Esq. Pamela N. Epstein Chief Compliance Officer CEO Greenbrier Holdings, LLC Green Wise Consulting Daniel D. Waite Bryna Dahlin CEO/Founder Partner Live Well Organix, LLC Flener IP & Business Law 8 Susan Ameel Josh Levine Founder and Partner Founder and Partner Global Regulatory Risk Advisors, LLC Global Regulatory Risk Advisors, LLC Jessica Passman, Esq. Bryan Passman Founder and COO Founder and CEO Hunter + Esquire Hunter + Esquire Nathan Howard Peter Belsito Co-founder & President CEO & Co-Founder East Fork Cultivars 3BC LLC Alan Hofman Matt Locati COO Managing Member GreenRx-id Cannalytics Capital LLC Mark Passerini Manndie Tingler, M.S. Co-Founder Chief Executive Officer The Om of Medicine Silver Leaf Events Kimberly Ross, PhD Chief Compliance Officer Peak Compliance 9 National Cannabis Industry Association (NCIA) FDA Public Comments Submission (Docket FDA-2019-N-1482) TABLE OF CONTENTS Introduction ........................................................................ 11 Questions Posed by FDA ........................................................................ 15 Health and Safety Risks ........................................................................ 15 Question 1 ........................................................................ 15 Question 2 ........................................................................ 21 Question 3 ........................................................................ 22 Question 4 ........................................................................ 23 Question 5 ........................................................................ 24 Question 6 ........................................................................ 25 Manufacturing and Product Quality ........................................................................ 27 Question 1 ........................................................................ 27 Question
Load more

Recommended publications
  • Drug Interactions: a Napdi Center Recommended Approach S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/05/07/dmd.118.081273.DC1 1521-009X/46/7/1046–1052$35.00 https://doi.org/10.1124/dmd.118.081273 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:1046–1052, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Perspective Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product–Drug Interactions: A NaPDI Center Recommended Approach s Emily J. Johnson,1 Vanessa González-Peréz,2 Dan-Dan Tian, Yvonne S. Lin, Jashvant D. Unadkat, Allan E. Rettie, Danny D. Shen, Jeannine S. McCune, and Mary F. Paine Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington (Y.S.L., J.D.U., A.E.R., D.D.S., J.S.M., M.F.P.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (E.J.J., V.G.-P., D.-D.T., Downloaded from M.F.P.); Department of Pharmaceutics (Y.S.L., J.D.U., D.D.S., J.S.M.) and Department of Medicinal Chemistry (A.E.R.), University of Washington, Seattle, Washington; and Department of Population Sciences, City of Hope, Duarte, California (J.S.M.) Received March 2, 2018; accepted May 3, 2018 dmd.aspetjournals.org ABSTRACT Pharmacokinetic interactions between natural products (NPs) and pharmacokinetic NPDIs. Guided information-gathering tools were used conventional medications (prescription and nonprescription) are a long- to score, rank, and triage NPs from an initial list of 47 candidates. standing but understudied problem in contemporary pharmacotherapy.
    [Show full text]
  • To Download the PDF File
    Biological Activities of Selected Dietary Apiaceae, Lamiaceae, and Fabaceae By Huang Huang A Thesis Submitted to the Faculty of Graduate Studies and Research of Carleton University, in partial fulfillment of the requirements for the degree of a Master of Science in Biology Department of Biology Carleton University Ottawa, ON, Canada 2010 © Copyright 2010, Huang Huang i Library and Archives Blbliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de l'6dition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 OttawaONK1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-71582-6 Our file Notre reference ISBN: 978-0-494-71582-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Blbliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par Nntemet, preter, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • When It Comes to Cannabis Potency?
    Testimony Should Canada “Start Low and Go Slow” When It Comes to Cannabis Potency? CT-­492 Testimony presented before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada on May 7, 2018. C O R P O R A T I O N For more information on this publication, visit www.rand.org/pubs/testimonies/CT492.html Testimonies RAND testimonies record testimony presented or submitted by RAND associates to federal, state, or local legislative committees; government-appointed commissions and panels; and private review and oversight bodies. Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation RA® is a registered trademark. Limited Print andElectronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html. www.rand.org Should Canada “Start Low and Go Slow” When It Comes to Cannabis Potency? Testimony of Beau Kilmer1 The RAND Corporation2 Before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada May 7, 2018 hairperson Eggleton, Deputy Chairperson Petitclerc, Deputy Chairperson Seidman, and other distinguished members of the Standing Committee on Social Affairs, Science, and C Technology, thank you very much for the opportunity to testify before you today.
    [Show full text]
  • Clearing the Smoke on Cannabis Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals
    7 Clearing the Smoke on Cannabis Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Key Points • Edible cannabis products, cannabis extracts and cannabis topicals have unique health and safety risks that are not inherent to dried cannabis. • High-potency cannabis extracts increase the risk of over-intoxication more This is the seventh in a series of than dried cannabis. Although limited, the available evidence indicates that reports that reviews the effects of frequent use of these products is associated with problematic cannabis use, cannabis use on various aspects of cannabis use disorder and mental health disorders. human functioning and development. • Edible cannabis products can increase the risk of over-consumption and Other reports in this series address subsequent over-intoxication and impairment. Because when unpackaged they look like ordinary food and beverage products, edible cannabis products the link between regular cannabis use also increase the risk of unintentional ingestion, especially by children. and mental health, regular cannabis • Research on cannabis topicals, including the use of topical and transdermal use and cognitive functioning, maternal cannabidiol products, is limited. There is, however, growing interest among cannabis use during pregnancy, dermatologists and consumers in these cannabis products. cannabis use and driving, respiratory • The health impacts associated with long-term use of edible cannabis and cardiovascular effects of smoking products, cannabis extracts and cannabis topicals are not known. cannabis, and the medical use of • Public education efforts will play an important role in mitigating the harms cannabis and cannabinoids. This series associated with new cannabis products.
    [Show full text]
  • Herbal Pharmacy
    ISSN: 2644-2957 DOI: 10.33552/OJCAM.2020.04.000580 Online Journal of Complementary & Alternative Medicine Opinion Article Copyright © All rights are reserved by M’Lou Barnett Herbal Pharmacy M’Lou Barnett* Integrative Medicine Fellow, North Western University of Louisiana, USA *Corresponding author: M’Lou Barnett, Integrative Medicine Fellow, North Received Date: March 20, 2020 Western University of Louisiana, USA. Published Date: May 14, 2020 Opinion With 50% of Americans utilizing Complementary Alternative know. Nurses & health professionals will have a better knowledge Medicines, knowledge of herbal supplements is limited among Surgery does not cure or benefit all illnesses, as nurses astutely of Herbal Pharmacy to better inform their patients. the general population. Unfortunately, most Americans rely on the advice of health food store employees to select botanical GAIA Herbs are the Best Brands of Herbal Medicine supplements. Aloe Vera-RX: Gel soothes pain & Promotes healing of wounds. The top Herbal supplements will be presented to educate Ashwagandha-RX: Calming adaptogen for anxiety, Stress, nurses. These include Aloe Vera, Ashwagandha, Black Cohosh, insomnia & Improving Cognitive function. Butterbur, California Poppy, Capsicum, Chamomile, Cinnamon, Dandelion, Echinacea, Elderberry, Evening Primrose, Fennel, Black Cohosh-RX: sweats, sleep disturbances, irritability); Premenstrual Syndrome & Feverfew, Garlic, Ginger, Ginkgo, Ginseng, Goldenseal, Green Tea, Menopausal Symptoms (hot flashes, night Hibiscus, Horse Chestnut, Kava, Lemon Balm, Licorice, Milk Thistle, Dysmenorrhea. Peppermint, Red Yeast Rice, St. John’s Wort, Saw Palmetto, Skullcap, Butterbur-RX: Allergies & migraine prophylaxis. Soy, Tea Tree Oil, Turmeric, Uva Ursi & Valerian. California Poppy-RX: Insomnia, Sedation, Aches, Nervous Each herb topics will include: Common Latin Binomial Name, Agitation, Prolong sleep & Anxiolytic.
    [Show full text]
  • The Role of Cannabinoids in Dermatology
    COMMENTARY The role of cannabinoids in dermatology Jessica S. Mounessa, BS,a,b Julia A. Siegel, BA,c Cory A. Dunnick, MD,a,b and Robert P. Dellavalle, MD, PhD, MSPHa,b Aurora and Denver, Colorado, and Worcester, Massachusetts Key words: cannabinoid; cannabis; dermatitis; endocannabinoid; inflammatory skin disease; keratinocyte carcinoma; melanoma; palmitoylethanolamide; pruritus; skin cancer; tetrahydrocannabinol. wenty-eight states currently allow for Abbreviations used: comprehensive public medical cannabis programs, and this number continues to CB1: cannabinoid 1 T1 CB2: cannabinoid 2 grow. Approximately 1 in 10 adult cannabis users in 2 PEA: palmitoylethanolamide the United States use it for medical purposes. THC: tetrahydrocannabinol Numerous studies have investigated its uses for chronic pain, spasticity, anorexia, and nausea. In recent years, researchers have also investigated its work independently of descending inhibitory use for the treatment of dermatologic conditions pathways.5 including pruritus, inflammatory skin disease, and Cannabinoids may also have anti-inflammatory skin cancer. properties useful for the treatment of both allergic Perhaps the most promising role for cannabinoids contact dermatitis and atopic dermatitis. Petrosino is in the treatment of itch. In a study of patients with et al6 reported that mice released PEA in response to uremic pruritus on maintenance hemodialysis, 2,4-dinitrofluorobenzeneeinduced allergic contact topical application of a cream with structured dermatitis as an endogenous protective agent. PEA physiologic lipids (derma membrane structure) and may work to reduce later stages of allergic contact endogenous cannabinoids applied twice daily for dermatitis, including mast-cell infiltration, angiogen- 3 weeks completely eliminated pruritus in 8 of 21 esis, and itching.7-9 Tetra-hydrocannabinol (THC) patients (38%).
    [Show full text]
  • Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development
    Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 238482, 26 pages http://dx.doi.org/10.1155/2015/238482 Review Article Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development Charu Sharma,1 Bassem Sadek,2 Sameer N. Goyal,3 Satyesh Sinha,4 Mohammad Amjad Kamal,5,6 and Shreesh Ojha2 1 Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE 2Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE 3DepartmentofPharmacology,R.C.PatelInstituteofPharmaceuticalEducation&Research,Shirpur,Mahrastra425405,India 4Department of Internal Medicine, College of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA 5King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia 6Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia Correspondence should be addressed to Shreesh Ojha; [email protected] Received 24 April 2015; Accepted 24 August 2015 Academic Editor: Ki-Wan Oh Copyright © 2015 Charu Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The cannabinoid molecules are derived from Cannabis sativa plant which acts on the cannabinoid receptors types 1 and 2 (CB1 and CB2) which have been explored as potential therapeutic targets for drug discovery and development. Currently, there are 9 numerous cannabinoid based synthetic drugs used in clinical practice like the popular ones such as nabilone, dronabinol, and Δ - tetrahydrocannabinol mediates its action through CB1/CB2 receptors.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Nurturing New Growth Canada Gets Ready for Cannabis 2.0 Table of Contents
    Nurturing new growth Canada gets ready for Cannabis 2.0 Table of contents Introduction 1 Cannabis 2.0: Canadian survey insights 4 Perspectives on Cannabis 2.0 22 The way forward: Thriving in a Cannabis 2.0 world 30 Remain bold 32 Nurturing new growth | Canada gets ready for Cannabis 2.0 | Introduction Introduction ll eyes remain on Canada as it prepares for the next stage of cannabis legalization—a step that will keep A the country firmly at the vanguard of a societal revolution and a new industry exploding with potential. “Cannabis 2.0” will see edibles containing cannabis and cannabis concentrates become legal on October 17, 2019. Their legalization will mean seven classes of cannabis products will be approved for sale in Canada, as dried cannabis, cannabis oil, fresh cannabis, cannabis plants, cannabis plant seeds, were legalized in 2018. The speed with which Canada’s cannabis industry has evolved over the past 18 months has been truly remarkable. In this, our third annual report on Canada’s cannabis industry, Deloitte has taken a broader approach in our research. As in previous years, we conducted comprehensive market research to understand Canadian consumer sentiment on cannabis edibles and other alternative products coming with Cannabis 2.0 legalization. The introduction of these new products is creating new opportunities in product mixes, reaching new cannabis consumers not fully comfortable with traditional consumption methods currently available. 1 Nurturing new growth | Canada gets ready for Cannabis 2.0 | Introduction As well, we explore trends and Our research suggests that the new However, we do need to acknowledge issues affecting the cannabis sector, alternative cannabis products becoming that Canada’s legal recreational drawing on extensive interviews and legal in late 2019 will be a significant cannabis industry is still in its infancy.
    [Show full text]
  • Cannabis and Its Secondary Metabolites: Their Use As Therapeutic Drugs, Toxicological Aspects, and Analytical Determination
    medicines Review Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination Joana Gonçalves 1,†, Tiago Rosado 1,†, Sofia Soares 1,†, Ana Y. Simão 1,†,Débora Caramelo 1,†, Ângelo Luís 1,† , Nicolás Fernández 2,†,Mário Barroso 3, Eugenia Gallardo 1 and Ana Paula Duarte 1,* 1 Centro de Investigação em Ciências da Saúde, Faculdade de Ciências da Saúde da Universidade da Beira Interior (CICS-UBI), 6200-506 Covilhã, Portugal; [email protected] (J.G.); [email protected] (T.R.); sofi[email protected] (S.S.); [email protected] (A.Y.S.); [email protected] (D.C.); afl[email protected] (Â.L.); [email protected] (E.G.) 2 Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA). Junín 956 7mo piso. Ciudad Autónoma de Buenos Aires (CABA), Buenos Aires C1113AAD, Argentina; [email protected] 3 Serviço de Química e Toxicologia Forenses, Instituto de Medicina Legal e Ciências Forenses - Delegação do Sul, 1169-201 Lisboa, Portugal; [email protected] * Correspondence: [email protected]; Tel.: +35-127-532-9002 † These authors contributed equally to this work. Received: 31 January 2019; Accepted: 18 February 2019; Published: 23 February 2019 Abstract: Although the medicinal properties of Cannabis species have been known for centuries, the interest on its main active secondary metabolites as therapeutic alternatives for several pathologies has grown in recent years. This potential use has been a revolution worldwide concerning public health, production, use and sale of cannabis, and has led inclusively to legislation changes in some countries.
    [Show full text]
  • Goldenseal Assistant Authors: Kathleen Bennett MS, Kevin Spelman Phd, Michael Tims Phd
    An Appalachian Plant Monograph Chief author and editor: Andrew Pengelly PhD. Goldenseal Assistant authors: Kathleen Bennett MS, Kevin Spelman PhD, Michael Tims PhD. Hydrastis canadensis L. Peer review board: Paul Bergner AHG, Hans Wolmuth PhD. 1. Taxonomy Editorial team: Bevin Clare MS, Mimi Hernandez MS, James Snow Hydrastis canadensis L. MA, Amanda Vickers MS. Family: Ranunculaceae (buttercup family) Hydrastis is a monotypic genus, which some authors have placed in a Citation Instruction: Pengelly, A., separate family – Hydrastidaceae (Tobe & Keating, 1985) – though Bennett, K., Spelman, K., & Tims, M. more recent genetic studies confirm H. canadensis as the basal branch (2012). Appalachian plant of the Ranunculaceae, albeit with close ties to the Berberidaceae family monographs: Hydrastis canadensis L., (Ro, Keener, & McPheron, 1997; Chu, Li, & Qi, 2006). goldenseal. Appalachian Center for EthnoBotanical Studies. Common names: golden seal, eyebalm, eyeroot, golden root, ground raspberry, Indian dye, Indian turmeric, jaundice root, orange root, Cover illustration By Peggy Duke yellowroot, yellow pucoon. APPALACHIAN PLANT MONOGRAPHS Hydrastis canadensis 1. Taxonomy 1 2. Botanical description and 2. Botanical description distribution and distribution 2 Hydrastis canadensis is an herbaceous perennial growing from a short yellow rhizome. The rhizome has a knotty appearance bearing 3. Traditional use 3 remnants of stems or stem scars (Tobe & Keating, 1985). During the first year vegetative growth consists of a pair of leaf-like cotyledons on 4. Phytochemistry 4 long petioles. In the second year a few inch long ‘footstalk’ emerges bearing one palmately-lobed or maple-shaped leaf with biserrate 5. Pharmacology and margins near the apex. Over the next two years a true stem arises attaining a height of one foot or more, bearing two or three petiolate toxicology 11 leaves arranged alternately on the stem.
    [Show full text]
  • Combining Herbs and Essential Oils This Presentation Explores How
    Hawthorn University Holistic Health and Nutrition Webinar Series 2017 www.hawthornuniversity.org Presented by David Crow, L.Ac. Combining Herbs and Essential Oils This presentation explores how essential oils and aromatherapy can be integrated with herbal treatments for added therapeutic effects and benefits. It explores which essential oils can be safely combined, and how, with herbs according to therapeutic functions: ) Expectorant, mucolytic, decongestant and antitussive herbs ) Nervine relaxant, sedative and anxiolytic herbs ) Demulcent herbs ) Anti-spasmotic and analgesic herbs ) Antimicrobial herbs ) Cholagogue and laxative herbs ) Immune modulating and immune stimulating herbs ) Adaptogen, trophorestorative and neuroendocrine regulating herbs ) Antiinflammatory herbs ) Emmenagogue and uterine tonic herbs Learning Objectives: ) When and how essential oils and aromatherapy are a primary, adjunct or contraindicated treatment ) To understand the compatibility or lack of compatibility of specific groups and species of essential oils and specific groups and species of herbs ) Simple combinations of herbs and essential oils for specific therapeutic benefits Introduction ) General suggestions for how to use safely therapeutic groups of essential oils in combinations with groups of herbs. ) Does not give detailed methods of use of the oils. ) Does not give any specific dosages or uses of herbs. ) Please do not use herbs without studying them in detail. ) Please use essential oils according to safe methods of applications ) Do not take internally ) Do not apply undiluted to the skin Difficulties classifying essential oils into therapeutic categories Where do the claims about therapeutic actions of essential oils come from? 1. Empirical evidence from long history of use of aromatic plants 2. Modern scientific studies 3. Claims made about essential oils through MLM companies and spread on the internet Many claims about the functions of essential oils are not substantiated or established.
    [Show full text]